Core Viewpoint - China National Pharmaceutical Group Co., Ltd. (China Biopharmaceutical) announced a total acquisition of Hangzhou Hejiya Biopharmaceutical Co., Ltd. for RMB 1.2 billion, aiming to enhance its capabilities in the small interfering RNA (siRNA) drug development sector [1][2]. Group 1: Acquisition Details - The acquisition price for Hejiya Biopharmaceutical is set at RMB 1.2 billion [1]. - Hejiya Biopharmaceutical specializes in the research and development of innovative siRNA drugs, focusing on significant clinical value in the treatment of metabolic diseases, cardiovascular diseases, and neurological disorders [1]. Group 2: Strategic Importance - The acquisition is expected to strengthen China Biopharmaceutical's core competitiveness in the siRNA field and expand its presence in the global market for chronic disease treatment, which is valued in the trillions [2]. - The merger will leverage the existing clinical development and commercial expansion experience of China Biopharmaceutical, providing strong momentum for sustainable growth and long-term value creation for shareholders [2]. Group 3: Innovation and Future Prospects - Hejiya has successfully overcome delivery technology bottlenecks for siRNA drugs across multiple tissues, achieving long-lasting gene silencing effects with a single administration [1]. - The collaboration is anticipated to accelerate drug development processes and expand the application of siRNA technology to address unmet medical needs in various disease areas [2].

（来源：药研网） 1月13日，中国生物制药宣布全资收购赫吉亚，扩展布局siRNA赛道。 根据买卖协议，卖方有条件地同意出售，而买方有条件地同意收购赫吉亚100%的股权，最高基础代价为人民币12亿元（可下调）， 部分以现金支付，部分以代价股份支付。于交割时届时，赫吉亚将成为中国生物制药的间接全资附属公司。 赫吉亚是一家专注于小干扰核酸（siRNA）创新药研发的先锋生物医药企业，已构建从靶点发现到临床概念验证（POC）的一体化创 新药物开发体系，重点布局减重代谢、心脑血管、神经系统三大慢性病领域。 2025年siRNA领域全球披露交易总额将超350亿美元，同比增长率超过40%。作为siRNA创新药研发的先锋企业，赫吉亚成功攻克了多 个组织的递送突破技术瓶颈，实现对肝脏（单靶点/双靶点）、神经、肺部、肾脏、脂肪等多组织的精准靶向，达成单次给药即可实 现长效沉默靶基因的效果，其显著优异的疗效、长效性及安全性已在临床前研经过研究与临床试验的双重验证。通过此次收购，本集 团将构建下一代心血管治疗创新产品线，完善减重新布局代谢领域，拓展万亿级慢性病管理市场新版图。 | | 赫吉亞的股東 | 概約所有權 | 各名賣方應佔基 ...